{"id":"19009392","title":"Blueprint Medicines Reports Second Quarter 2023 Results","author":null,"feed":"PRTGAM","feedName":"PR Newswire","published":"Wed Aug 2, 2023","image":"N/A","content":"

-- Achieved $39.9 million in AYVAKIT^®/AYVAKYT^® (avapritinib) net product revenues and $57.6 million in total revenues in the second quarter of 2023 --

-- AYVAKIT approved by the FDA for the treatment of adults with indolent systemic mastocytosis on May 22, 2023 --

","related":[{"id":"1527731","title":"Kepler Capital Sticks to Their Hold Rating for Redcare Pharmacy (0RJT)","slug":"kepler-capital-sticks-to-their-hold-rating-for-redcare-pharmacy-0rjt","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527729","title":"Kepler Capital Sticks to Their Hold Rating for Tubacex (0KD1)","slug":"kepler-capital-sticks-to-their-hold-rating-for-tubacex-0kd1","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527727","title":"Kepler Capital Reaffirms Their Buy Rating on Viscofan (0MKW)","slug":"kepler-capital-reaffirms-their-buy-rating-on-viscofan-0mkw","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527725","title":"Kepler Capital Reaffirms Their Hold Rating on Fnac Darty SA (0QSH)","slug":"kepler-capital-reaffirms-their-hold-rating-on-fnac-darty-sa-0qsh","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527723","title":"Kepler Capital Keeps Their Buy Rating on Lectra SA (0IVJ)","slug":"kepler-capital-keeps-their-buy-rating-on-lectra-sa-0ivj","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527721","title":"Kepler Capital Remains a Buy on Tomra Systems ASA (0KV7)","slug":"kepler-capital-remains-a-buy-on-tomra-systems-asa-0kv7","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527719","title":"Kepler Capital Remains a Buy on Xior Student Housing N.V. (0RD8)","slug":"kepler-capital-remains-a-buy-on-xior-student-housing-n-v-0rd8","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527717","title":"Kepler Capital Sticks to Their Buy Rating for INFICON Holding AG (IFCN)","slug":"kepler-capital-sticks-to-their-buy-rating-for-inficon-holding-ag-ifcn","feedName":"Tipranks","published":"15 minutes ago","categories":[]},{"id":"1527715","title":"Kepler Capital Sticks to Their Buy Rating for Duni AB (2DU)","slug":"kepler-capital-sticks-to-their-buy-rating-for-duni-ab-2du","feedName":"Tipranks","published":"15 minutes ago","categories":[]}],"sourceId":"prnews-2023-8-2-blueprint-medicines-reports-second-quarter-2023-results","media":"text","thumbnail":"N/A","canonicalUrl":"https://www.prnewswire.com/news-releases/blueprint-medicines-reports-second-quarter-2023-results-301891126.html","feedUrl":"https://www.prnewswire.com/","slug":"blueprint-medicines-reports-second-quarter-2023-results"}

Latest in

More

Blueprint Medicines Reports Second Quarter 2023 Results